Contact Dermatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major contact dermatitis markets reached a value of US$ 10.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 19.4 Billion by 2034, exhibiting a growth rate (CAGR) of 5.46% during 2024-2034.
The contact dermatitis market has been comprehensively analyzed in IMARC's new report titled "Contact Dermatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Contact dermatitis refers to a common skin condition distinguished by skin inflammation that develops when the skin comes into direct proximity with specific substances, known as irritants or allergens. It is not contagious and typically occurs only in the areas of the skin that come into contact with the triggering material. The most common symptoms include itching, redness, as well as swelling in the affected area. The skin may become dry and scaly, developing small bumps or blisters that can ooze or crust over time. The severity of the indications can vary depending on the patient's sensitivity to the triggering substance and the duration and intensity of the contact. Diagnosing the condition involves a comprehensive evaluation of the patient's medical history, a thorough physical examination, and sometimes additional tests. The dermatologist will inquire about potential triggers, recent exposures to irritants or allergens, and the timeline and characteristics of the skin symptoms. The physical exam focuses on the affected skin, looking for redness, swelling, blistering, or other signs of inflammation. In some cases, patch testing may be performed to identify specific allergens responsible for contact dermatitis.
The increasing cases of exposure to harsh chemicals found in cleaning products, detergents, solvents, acids, alkalis, etc., which strip the skin's natural oils, disrupt the skin barrier, and cause inflammation, are primarily driving the contact dermatitis market. In addition to this, the escalating incidences of contact with common allergens, including metals present in jewelry, certain plants like poison ivy and poison oak, fragrances in perfumes and cosmetics, etc., that trigger an immune response resulting in redness and itching, are creating a positive outlook for the market. Moreover, the widespread adoption of topical corticosteroid creams and ointments, since they help to alleviate the discomfort as well as reduce inflammation and itching associated with the ailment, is further bolstering the market growth. Additionally, the inflating application of immunomodulatory drugs, such as tacrolimus and pimecrolimus, for managing flare-ups and maintaining remission in sensitive areas of the skin is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of advanced targeted phototherapy devices that deliver light directly to affected regions, thereby reducing the exposure of healthy skin to UV radiation, is expected to drive the contact dermatitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the contact dermatitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for contact dermatitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the contact dermatitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the contact dermatitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the contact dermatitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current contact dermatitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the contact dermatitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the contact dermatitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the contact dermatitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of contact dermatitis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of contact dermatitis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of contact dermatitis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with contact dermatitis across the seven major markets?
What is the size of the contact dermatitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of contact dermatitis?
What will be the growth rate of patients across the seven major markets?
Contact Dermatitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for contact dermatitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the contact dermatitis market?
What are the key regulatory events related to the contact dermatitis market?
What is the structure of clinical trial landscape by status related to the contact dermatitis market?
What is the structure of clinical trial landscape by phase related to the contact dermatitis market?
What is the structure of clinical trial landscape by route of administration related to the contact dermatitis market?
The contact dermatitis market has been comprehensively analyzed in IMARC's new report titled "Contact Dermatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Contact dermatitis refers to a common skin condition distinguished by skin inflammation that develops when the skin comes into direct proximity with specific substances, known as irritants or allergens. It is not contagious and typically occurs only in the areas of the skin that come into contact with the triggering material. The most common symptoms include itching, redness, as well as swelling in the affected area. The skin may become dry and scaly, developing small bumps or blisters that can ooze or crust over time. The severity of the indications can vary depending on the patient's sensitivity to the triggering substance and the duration and intensity of the contact. Diagnosing the condition involves a comprehensive evaluation of the patient's medical history, a thorough physical examination, and sometimes additional tests. The dermatologist will inquire about potential triggers, recent exposures to irritants or allergens, and the timeline and characteristics of the skin symptoms. The physical exam focuses on the affected skin, looking for redness, swelling, blistering, or other signs of inflammation. In some cases, patch testing may be performed to identify specific allergens responsible for contact dermatitis.
The increasing cases of exposure to harsh chemicals found in cleaning products, detergents, solvents, acids, alkalis, etc., which strip the skin's natural oils, disrupt the skin barrier, and cause inflammation, are primarily driving the contact dermatitis market. In addition to this, the escalating incidences of contact with common allergens, including metals present in jewelry, certain plants like poison ivy and poison oak, fragrances in perfumes and cosmetics, etc., that trigger an immune response resulting in redness and itching, are creating a positive outlook for the market. Moreover, the widespread adoption of topical corticosteroid creams and ointments, since they help to alleviate the discomfort as well as reduce inflammation and itching associated with the ailment, is further bolstering the market growth. Additionally, the inflating application of immunomodulatory drugs, such as tacrolimus and pimecrolimus, for managing flare-ups and maintaining remission in sensitive areas of the skin is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of advanced targeted phototherapy devices that deliver light directly to affected regions, thereby reducing the exposure of healthy skin to UV radiation, is expected to drive the contact dermatitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the contact dermatitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for contact dermatitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the contact dermatitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the contact dermatitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the contact dermatitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current contact dermatitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the contact dermatitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the contact dermatitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the contact dermatitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of contact dermatitis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of contact dermatitis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of contact dermatitis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with contact dermatitis across the seven major markets?
What is the size of the contact dermatitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of contact dermatitis?
What will be the growth rate of patients across the seven major markets?
Contact Dermatitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for contact dermatitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the contact dermatitis market?
What are the key regulatory events related to the contact dermatitis market?
What is the structure of clinical trial landscape by status related to the contact dermatitis market?
What is the structure of clinical trial landscape by phase related to the contact dermatitis market?
What is the structure of clinical trial landscape by route of administration related to the contact dermatitis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CONTACT DERMATITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CONTACT DERMATITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CONTACT DERMATITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CONTACT DERMATITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CONTACT DERMATITIS - UNMET NEEDS
10 CONTACT DERMATITIS - KEY ENDPOINTS OF TREATMENT
11 CONTACT DERMATITIS - MARKETED PRODUCTS
11.1 List of Contact Dermatitis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CONTACT DERMATITIS - PIPELINE DRUGS
12.1 List of Contact Dermatitis Pipeline Drugs Across the Top 7 Markets
12.1.1 EB01 - Edesa Biotech
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CONTACT DERMATITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CONTACT DERMATITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CONTACT DERMATITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Contact Dermatitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Contact Dermatitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Contact Dermatitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Contact Dermatitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Contact Dermatitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Contact Dermatitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Contact Dermatitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Contact Dermatitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Contact Dermatitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Contact Dermatitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Contact Dermatitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Contact Dermatitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Contact Dermatitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Contact Dermatitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Contact Dermatitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Contact Dermatitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Contact Dermatitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Contact Dermatitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Contact Dermatitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Contact Dermatitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Contact Dermatitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Contact Dermatitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Contact Dermatitis - Access and Reimbursement Overview
16 CONTACT DERMATITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CONTACT DERMATITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CONTACT DERMATITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CONTACT DERMATITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CONTACT DERMATITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CONTACT DERMATITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CONTACT DERMATITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CONTACT DERMATITIS - UNMET NEEDS
10 CONTACT DERMATITIS - KEY ENDPOINTS OF TREATMENT
11 CONTACT DERMATITIS - MARKETED PRODUCTS
11.1 List of Contact Dermatitis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CONTACT DERMATITIS - PIPELINE DRUGS
12.1 List of Contact Dermatitis Pipeline Drugs Across the Top 7 Markets
12.1.1 EB01 - Edesa Biotech
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CONTACT DERMATITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CONTACT DERMATITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CONTACT DERMATITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Contact Dermatitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Contact Dermatitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Contact Dermatitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Contact Dermatitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Contact Dermatitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Contact Dermatitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Contact Dermatitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Contact Dermatitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Contact Dermatitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Contact Dermatitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Contact Dermatitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Contact Dermatitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Contact Dermatitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Contact Dermatitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Contact Dermatitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Contact Dermatitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Contact Dermatitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Contact Dermatitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Contact Dermatitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Contact Dermatitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Contact Dermatitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Contact Dermatitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Contact Dermatitis - Access and Reimbursement Overview
16 CONTACT DERMATITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CONTACT DERMATITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CONTACT DERMATITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
